In a hospice patient with diabetes mellitus who is taking insulin glargine (U100) 15 units subcutaneously at bedtime, should blood glucose be routinely checked?

Blood Glucose Monitoring in Hospice Patients on Insulin Glargine

In hospice patients on insulin glargine, blood glucose monitoring should be significantly reduced or discontinued entirely, with the primary goal being prevention of symptomatic hypoglycemia and hyperglycemia rather than achieving tight glycemic control. 1, 2

Rationale for Reduced Monitoring in Hospice

The goals of diabetes management fundamentally shift at end of life. Strict glucose control is not necessary in hospice care, and simplification of regimens—including reduction in blood glucose monitoring frequency—is explicitly recommended. 1, 2 The focus transitions from long-term complication prevention to immediate comfort, quality of life, and prevention of distressing symptoms like severe hypoglycemia, dehydration from hyperglycemia, and symptomatic glucosuria 1, 3, 2.

Acceptable Glucose Targets in Hospice

Guidelines specifically state that glycemic levels of 200-300 mg/dL are acceptable in hospice patients taking glucose-lowering medications 3. More broadly, glucose levels >250 mg/dL (13.9 mmol/L) may be acceptable in terminally ill patients with short life expectancy 4, 5, 6. These relaxed targets eliminate the need for frequent monitoring that would be required to maintain tighter control.

When to Check Blood Glucose

Rather than routine scheduled monitoring, blood glucose should be checked only when clinically indicated:

• When the patient exhibits symptoms suggesting hypoglycemia (confusion, diaphoresis, tremor, altered mental status)
• When symptoms of severe hyperglycemia occur (excessive thirst, polyuria, dehydration, altered mental status)
• If there are concerns about medication-related adverse effects
• During acute illness or significant changes in oral intake 1, 2

An alert-based strategy is more appropriate than routine monitoring: Check glucose if values are suspected to be <70 mg/dL or consistently >300 mg/dL over consecutive days, or if the patient appears symptomatic 1.

Insulin Management Considerations

For this patient on 15 units of insulin glargine at bedtime:

• The insulin regimen itself may warrant simplification or dose reduction in the hospice setting 1, 2
• Consider whether basal insulin alone (without correction doses) is sufficient, as this minimizes hypoglycemia risk 1
• Insulin doses may need reduction or discontinuation as oral intake declines 3
• The FDA label emphasizes that dosage adjustments require appropriate glucose monitoring 7, but in hospice, this means monitoring for symptoms rather than routine scheduled checks

Practical Implementation

A reasonable approach for this patient would be:

1. Discontinue routine scheduled blood glucose checks (no bedtime or fasting glucose monitoring)
2. Check glucose only if symptomatic (suspected hypoglycemia or severe hyperglycemia)
3. Monitor oral intake carefully as a proxy for insulin needs 1, 2
4. Consider reducing the insulin dose if oral intake is poor or unpredictable
5. Educate staff and family that glucose levels of 200-300 mg/dL are acceptable and do not require intervention 3

Common Pitfalls to Avoid

• Do not apply standard HEDIS quality measures or tight glycemic targets to hospice patients 3—these metrics are inappropriate and can lead to overtreatment
• Avoid the reflex to "treat the number" when incidental glucose values are mildly elevated
• Do not continue aggressive sliding scale insulin in hospice settings 3
• Recognize that hypoglycemia poses greater immediate harm than hyperglycemia in this population 1, 3, 2

The evidence consistently supports that comfort and dignity take precedence over glycemic metrics in hospice care 1, 3, 2. Recent quality improvement data from hospice units demonstrates that simplified insulin protocols with reduced monitoring can successfully prevent critical glucose values 8.